Physician profile
Lizy Thomas
NPI 1104902600
$5,349.78
in general payments reported to CMS, 2019-2025
41 companies · $878 in 2025
The $878 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,681 · 2020: $311 · 2021: $426 · 2022: $329 · 2023: $846 · 2024: $878 · 2025: $878.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,602.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,602.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,024.64 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $545.40 | 2019-2025 | Farxiga, Airsupra |
| Pfizer INC. | $528.16 | 2019-2025 | |
| Abbvie INC. | $496.41 | 2019-2025 | Ubrelvy, Qulipta, Linzess |
| Lilly USA, LLC | $399.72 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $282.42 | 2019-2025 | Xifaxan |
| Amgen INC. | $246.34 | 2019-2025 | Evenity, Tavneos, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $205.48 | 2019-2025 | Jardiance |
| Abbott Laboratories | $169.33 | 2021-2025 | Freestyle Libre 3, Proclaim |
| Merck Sharp & Dohme LLC | $161.17 | 2019-2024 | Gardasil, Gardasil 9, Capvaxive |
| Celltrion USA INC. | $137.83 | 2024-2025 | Vegzelma |
| Madrigal Pharmaceuticals | $99.00 | 2025 | Rezdiffra |
| Janssen Biotech, INC. | $97.71 | 2023-2025 | Stelara, Tremfya |
| Exact Sciences Corporation | $85.86 | 2023-2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $72.81 | 2019-2020 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lizy Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.